Long‐term 52‐week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series

Abstract

Apremilast has demonstrated a favourable safety profile for the treatment of psoriasis based on its pivotal randomized controlled trials (RCTs), ESTEEM 1 and 2.1,2 One-year safety data suggested that apremilast did not increase exposure-adjusted incidence of adverse events (AEs) during long-term treatment.1,2 Furthermore, approximately half of the reported nausea and diarrhea AEs resolved within one month of treatment in RCTs.1,2 Our co-authors previously reported the real-world 16-week safety outcomes of apremilast in psoriasis patients. This article is protected by copyright. All rights reserved.